Human Embryonic Stem Cell (hESC) Research 2014-2022 - Global Strategic Business Report 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jul 9, 2018--The “Human Embryonic Stem Cell (hESC) Research - Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.
Annual estimates and forecasts are provided for the period 2014 through 2022. Market data and analytics are derived from primary and secondary research.
This report analyzes the Global market for Human Embryonic Stem Cell (hESC) Research in US$ Million.
The report profiles 25 companies including many key and niche players such as:Astellas Institute of Regenerative Medicine (US) Asterias Biotherapeutics, Inc. (US) BD Biosciences (US) Cell Cure Neurosciences Ltd. (Israel) Cellular Dynamics International (US) GE Healthcare (UK) MilliporeSigma (US) PerkinElmer, Inc. (US) Reliance Life Sciences Ltd. (India) Research & Diagnostics Systems, Inc. (US) SABiosciences Corp. (US) STEMCELL Technologies, Inc. (Canada) Stemina Biomarker Discovery, Inc. (US) Takara Bio, Inc. (Japan) TATAA Biocenter AB (Sweden) Thermo Fisher Scientific, Inc. (US) UK Stem Cell Bank (UK) ViaCyte, Inc. (US) Vitrolife AB (Sweden)
Key Topics Covered
1. INDUSTRY OVERVIEWStem Cells Research: A Sunrise Sector in Biotechnology Arena Human Embryonic Stem Cells An Introduction Embryonic Stem Cells Sources and Cell Culture Comparison on Adult and Embryonic Stem Cells Advantages and Drawbacks of Various Stem Cells Human Embryonic Stem Cells The Market Perspective Timeline for Embryonic Stem Cell Research Activities: Major Events from 1963 through 2014 Issues Hindering Development of hESC Research Consideration of Best Translational Pathways Pivotal in Ensuring Growth Of hESCs Ethical Issues and Technical Hurdles Bog Down hESC Research Teratomas No Longer an Impediment to Stem Cell Therapy Development Human Embryonic and Induced Pluripotent Stem Cell Research Trends Human Embryonic Stem Cell Research: Key Statistical Highlights Research Topics on hESC and hiPSC by Number of Papers Published: 2011-2013 Haploid Human Embryonic Stem Cell Line: The New Frontier Human Induced Pluripotent Stem Cells Remains Best Alternative for hESC
2. REGULATORY LANDSCAPE
3. HESC APPLICATION AND CLINICAL TRIALS
4. COMPETITIVE LANDSCAPE
5. REGIONAL MARKET OVERVIEW
6. RECENT INDUSTRY ACTIVITY
7. GLOBAL MARKET PERSPECTIVE
Total Companies Profiled: 25 (including Divisions/Subsidiaries 28)The United States (16) Canada (1) Japan (2) Europe (7) The United Kingdom (3)Rest of Europe (4) Asia-Pacific (Excluding Japan) (1) Middle East (1)
For more information about this report visit https://www.researchandmarkets.com/research/gw6s9t/human_embryonic?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180709005440/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Stem Cells
INDUSTRY KEYWORD: STEM CELLS HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 07/09/2018 08:16 AM/DISC: 07/09/2018 08:16 AM